On the heels of yesterday’s announcement of positive study data from its phase III protocol for its flagship product Generex Oral-lyn, US-based Generex Biotechnology is updating on the products sales in India, where it is marketed and sold by Indian Pharmaceutical company, Shreya Life Sciences.
Generex Oral-lyn was approved in India for importation, commercial marketing and sale for the treatment of Type 1 and Type 2 diabetes and has been marketed under the brand name Oral Recosulin since January 27, 2009 in Mumbai and in the cities of Bangalore, Delhi, Kolkata, Chennai and Cochin since February 3, 2009.
Following the initial marketing campaign, Generex has announced that Shreya Life Sciences has to date procured Oral Recosulin orders from more than 60 doctors for over 100 patients.
“We believe that the rapid progress that our licensee has made in India reflects the demand for a pain-free insulin product,” said Ms Anna Gluskin, Generex’s CEO. “Since the educational introduction of Generex Oral-lyn in India last November, Shreya has designed and implemented a strategy to identify target markets in India and establish an initial customer base from which we expect sales to continue to grow.”
Generex Oral-lyn is a proprietary oral insulin spray product, the first non-injectable buccal insulin approved in India. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn is said to have no pulmonary side effects, and is delivered without pain via Generex’s proprietary RapidMist device, which is said to provide complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.